Holen Sie sich die Stockscreener-App
17.20
2.87%
0.48
Vorhandelsmarkt:
18.95
1.75
+10.17%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$16.72
Offen:
$16.83
24-Stunden-Volumen:
3.01M
Relative Volume:
1.33
Marktkapitalisierung:
$1.18B
Einnahmen:
$1.01B
Nettoeinkommen (Verlust:
$-204.71M
KGV:
-5.6042
EPS:
-3.0691
Netto-Cashflow:
$-29.67M
1W Leistung:
+14.93%
1M Leistung:
-5.29%
6M Leistung:
-18.13%
1J Leistung:
-19.17%
1-Tages-Spanne:
$16.80
$18.28
1-Wochen-Bereich:
$14.11
$18.28
52-Wochen-Spanne:
$9.98
$29.65
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
17.20 | 1.15B | 1.01B | -204.71M | -29.67M | -3.0691 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-19 | Hochstufung | Truist | Hold → Buy |
| 2026-03-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-23 | Hochstufung | Lake Street | Hold → Buy |
| 2026-02-20 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-01-27 | Fortgesetzt | TD Cowen | Buy |
| 2025-12-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-21 | Fortgesetzt | Stifel | Hold |
| 2025-09-08 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-06-16 | Eingeleitet | Truist | Hold |
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
Tandem Diabetes (TNDM) Receives Upgrade from Wells Fargo - GuruFocus
Wells Fargo upgrades Tandem Diabetes stock rating on pharmacy outlook By Investing.com - Investing.com Canada
What Does Tandem Diabetes Care's Upsized Convertible Note Offering Mean for Investors - Kavout
Citi Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $17 - Moomoo
Tandem Diabetes Care Hits Day High with 12.82% Surge in Stock Price - Markets Mojo
TNDM Maintained by Citigroup -- Price Target Lowered to $17 - GuruFocus
Tandem Diabetes Care Inc (TNDM) Shares Surge 12.9% -- What GF Sc - GuruFocus
Q1 2025 Tandem Diabetes Care Inc Earnings Call Transcript - GuruFocus
Tandem Diabetes Care Inc (BSP:T2ND34) Competitors 2026 - GuruFocus
Tandem Diabetes Care Inc (BSP:T2ND34) Stock News, Headlines & Updates - GuruFocus
Tandem Diabetes Care Inc (BSP:T2ND34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Tandem Diabetes Care Inc (BSP:T2ND34) Stock Price & 30 Year Financial Data - GuruFocus
Tandem Diabetes Care Inc Stock Operating Data - GuruFocus
Tandem Diabetes Care Inc (BSP:T2ND34) Stock Earnings Transcripts - GuruFocus
Citi Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Cuts Target Price to $17 - Moomoo
Goldman Sachs Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Cuts Target Price to $21 - Moomoo
Trading the Move, Not the Narrative: (TNDM) Edition - Stock Traders Daily
TNDM Stock Chart | TANDEM DIABETES CARE INC (NASDAQ:TNDM) - ChartMill
TNDM stock down following Q1 earnings & revenue beat, gross margin up - MSN
Tandem Diabetes Care (TNDM) Is Up 16.7% After Beating Q3 Views And Reaffirming 2025 EBITDA Target – Has The Bull Case Changed? - Yahoo Finance
Is Tandem Diabetes Care Inc (TNDM) a Bargain After 5.1% Drop? GF Value Says Undervalued - GuruFocus
Tandem Diabetes Care (TNDM) chair emeritus reports new RSU grant and vesting - Stock Titan
[Form 4] TANDEM DIABETES CARE INC Insider Trading Activity - Stock Titan
Tandem Diabetes (TNDM) director reports 10,220 RSU grant and 8,759-share vesting - Stock Titan
Tandem Diabetes Care (TNDM) director receives 5,110 restricted stock units grant - Stock Titan
Tandem Diabetes (TNDM) director adds shares through RSU grant and vesting - Stock Titan
Director at Tandem Diabetes (NASDAQ: TNDM) adds RSUs and shares - Stock Titan
Tandem Diabetes (TNDM) director receives 10,220 RSU grant as prior award vests - Stock Titan
Tandem Diabetes (TNDM) director gets 10,220 RSUs as 8,759 vest - Stock Titan
Tandem Diabetes (TNDM) director Twomey reports RSU grant and 8,759-unit vesting - Stock Titan
Shareholders back charter changes and equity plan at Tandem Diabetes (NASDAQ: TNDM) - Stock Titan
Reasons to hold Tandem Diabetes stock in your portfolio for now - MSN
TNDM Technical Analysis | Trend, Signals & Chart Patterns | TANDEM DIABETES CARE INC (NASDAQ:TNDM) - ChartMill
Small-Cap Stocks to Avoid: Wyndham, KBR, and Tandem Diabetes Care AnalysisNews and Statistics - IndexBox
Tandem Diabetes’s SWOT analysis: stock faces competitive headwinds By Investing.com - Investing.com Nigeria
Tandem Diabetes Care Inc Annual Shareholders Meeting Transcript - GuruFocus
Tandem Diabetes’s SWOT analysis: stock faces competitive headwinds - Investing.com
Tandem Diabetes (NASDAQ: TNDM) Form 144: 266 RSUs slated for sale - Stock Titan
Tandem Diabetes Care Stock Down 23% But Insiders Still In US$84k Profit - 富途牛牛
Tandem Diabetes (TNDM) CTO reports RSU vesting, ESPP share purchase and tax withholding - Stock Titan
Tandem Diabetes (TNDM) EVP reports RSU exercises, tax share withholding and trust holdings - Stock Titan
Tandem Diabetes Care (TNDM) legal chief reports RSU vesting, tax withholding and ESPP purchase - Stock Titan
Tandem Diabetes (TNDM) COO logs RSU vesting, tax withholding and ESPP purchase - Stock Titan
Tandem Diabetes (TNDM) exec gains shares via RSU vesting and ESPP - Stock Titan
Tandem Diabetes Care (TNDM) CEO reports RSU vesting, ESPP buy and tax withholding - Stock Titan
Tandem Diabetes (TNDM) CFO exercises RSUs and ESPP, increases share holdings - Stock Titan
Tandem Diabetes (TNDM) EVP gets RSU shares while company withholds stock for taxes - Stock Titan
Silver Economy Investing: Why the Healthcare Giants Are in Focus - TradingView
TNDM Maintained by B of A Securities -- Price Target Lowered to $25 - GuruFocus
Tandem Diabetes Care Price Target Cut to $25.00/Share From $35.00 by B of A Securities - Moomoo
Tandem Diabetes’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):